Trial reportJournal of autoimmunity2020
SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients.
Trial report in Journal of autoimmunity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- COVID-19 vaccine and the risk of flares in inflammatory arthritis: a systematic literature review and meta-analysis.Frontiers in immunology · 2024Pooled it
- Pooled it
- Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: a systematic review and meta-analysis.Rheumatology international · 2021Pooled it
- National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1.Journal of the American Academy of Dermatology · 2020Guideline
- Vasculitis syndromes: the pathogenic roles of COVID-19 and related vaccinations.Virology journal · 2025Review
- TAX1BP1 regulates the apoptosis of renal tubular epithelial cells in ischemia/reperfusion injury via the NF-kB/PMAIP1 signaling pathway.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Article
- Observational
- Prognostic factors and outcomes in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis: A retrospective single-center study from southern China.Pakistan journal of medical sciences · 2024Article
- Pandemic of the century: COVID-19 in inflammatory rheumatic diseases of a national cohort with 3,532 patients.Archives of rheumatology · 2024Article
- Article
- Mendelian randomization and Bayesian model averaging of autoimmune diseases and Long COVID.Frontiers in genetics · 2024Article
- Systemic lupus erythematosus nephritis and COVID-19 disease.Clinical rheumatology · 2023Article
- Factors Related to Severity, Hospitalization, and Mortality of COVID-19 Infection among Patients with Autoimmune Diseases.Tropical medicine and infectious disease · 2023Article
- Outcome of SARS-CoV2 infection in hematopoietic stem cell transplant recipients for autoimmune diseases.Journal of autoimmunity · 2023Observational
- Non-causal association of COVID-19 with systemic lupus erythematosus: Evidence from a bidirectional Mendelian randomization.The Journal of infection · 2023Article
- Review
- No genetic causal association between systemic lupus erythematosus and COVID-19.Frontiers in immunology · 2023Article
- A deep look into the storm: Israeli multi-center experience of coronavirus disease 2019 (COVID-19) in patients with autoimmune inflammatory rheumatic diseases before and after vaccinations.Frontiers in immunology · 2023Article
- The Course of COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases.Journal of clinical medicine · 2022Article
- Rapid Review of Medication Taking (Adherence) Among Patients With Rheumatic Diseases During the COVID-19 Pandemic.Arthritis care & research · 2022Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhether patients with autoimmune rheumatic diseases (ARD) have a higher risk for SARS-CoV-2 infection (COVID-19) and how SARS-CoV-2 pandemic impacts on adherence to therapy has not been fully elucidated. We assessed the rate and clinical presentation of COVID-19, and adherence to therapy in a large cohort of patients with ARD followed-up in a tertiary University-Hospital in Northeast Italy.
methodsBetween April 9th and April 25th
results916 patients (397 SLE, 182 AAV, 176 SSc, 111 RA, 50 IIM) completed the survey. 148 patients developed at least one symptom compatible with COVID-19 (cough 96, sore throat 64, fever 64, arthromyalgias 59, diarrhea 26, conjunctivitis 18, ageusia/hyposmia, 18). Among the 916 patients, 65 (7.1%) underwent SARS-CoV-2 nasopharyngeal swab (18 symptomatic and 47 asymptomatic), 2 (0.21%) tested positive, a proportion similar to that observed in the general population of the Veneto region. No deaths occurred. 31 patients (3.4%) withdrew ≥1 medication, mainly immunosuppressants or biologics. Adoption of social distancing was observed by 860 patients (93.9%), including 335 (36.6%) who adopted it before official lockdown.
conclusionsCOVID-19 incidence seems to be similar in our cohort compared to the general population. Adherence to therapy and to social distancing advise was high.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.